Neal Moser, MD
Pulmonary Disease · Crestview Hills, KYNPI 1295727618
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,470 of the $17,806 with a category attached, or 64.4%. 46 manufacturers reported payments, led by Intuitive Surgical at 33.7% of the total. Reporting peaked in 2023 at $7,872 and has fallen 74.0% since, to $2,048 in 2025. Among pulmonary disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 737 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$3K
- AstraZeneca$1K
- Boehringer Ingelheim$971
- Actelion Pharmaceuticals US, Inc.$901
- Grifols USA, LLC$879
- plus $5K from 40 others
What the payments were for
- Food & beverage$11,47064%
- Education$6,33636%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$3,000
- TEZSPIRE$674
- FASENRA$674
- AIRSUPRA$574
- BREZTRI$306
- remede System$172
- PURIFIED CORTROPHIN GEL$151
How this compares
$17,806 in reported general payments places this provider in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 46 | $552,670 |
| OpsumitMacitentan | 36 | $443,362 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 462 | $442,796 |
| Fasenra PenBenralizumab | 41 | $225,853 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 217 | $193,910 |
| AdempasRiociguat | 11 | $151,748 |
| NucalaMepolizumab | 27 | $119,456 |
| Dupixent PenDupilumab | 27 | $94,834 |
| Breo ElliptaFluticasone/Vilanterol | 167 | $88,334 |
| TezspireTezepelumab-Ekko | 14 | $58,037 |
| Spiriva RespimatTiotropium Bromide | 58 | $44,260 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 74 | $43,368 |
| DuleraMometasone/Formoterol | 35 | $15,472 |
| Spiriva HandihalerTiotropium Bromide | 14 | $13,986 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $11,925 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $2,636 | $661,653681 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $971 | $640,298178 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $901 | $443,36236 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Airsupra, Daliresp | $1,485 | $280,895308 claims |
| BayerAdempas | $148 | $151,74811 claims |
| MerckDulera | $192 | $15,47235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Crestview Hills
- Sai KonduriCrestview Hills$10K
- John McConnellLouisville$864K
- Erica GregonisRichmond$390K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.